Thyroglobulin antibodies in differentiated thyroid cancer

Area of Science:

• Endocrinology
• Oncology
• Clinical Chemistry

Background:

• Differentiated thyroid cancer (DTC) monitoring relies on serum thyroglobulin (Tg) assays.
• Serum thyroglobulin antibodies (TgAb) can interfere with Tg measurements, leading to underestimation.
• The clinical significance of TgAb in DTC follow-up requires further elucidation.

Purpose of the Study:

• To investigate the clinical significance of serum thyroglobulin antibodies (TgAb) in patients with differentiated thyroid cancer (DTC).
• To assess the impact of TgAb on the reliability of serum thyroglobulin (Tg) monitoring for DTC recurrence.
• To determine if TgAb can serve as a tumor marker in DTC patients.

Main Methods:

• Retrospective review of 40 DTC patients with TgAb between 1984-1996.
• Analysis of patient case notes for clinical data and recurrence information.
• Grouping patients by TgAb titre (high >1/100, low <1/100) to assess recurrence and survival.

Main Results:

• TgAb interfered with Tg measurements, failing to detect 92% of recurrences.
• TgAb acted as a tumor marker in 22.5% of patients with detectable TgAb.
• Development of TgAb was associated with tumor progression in some cases.
• 10-year overall survival was 69% for the entire group.

Conclusions:

• Serum thyroglobulin antibody (TgAb) presence should be routinely reported by laboratories with a caution regarding assay interference.
• Clinicians must recognize that thyroglobulin (Tg) measurements are unreliable in the presence of TgAb.
• The development of TgAb can be an indicator of active differentiated thyroid cancer (DTC) and may function as a tumor marker.